R
Radiopharm Theranostics Ltd
NASDAQ:RADX
Radiopharm Theranostics Ltd
NASDAQ:RADX
Price:
0.8901
USD
-10.37%
Market Closed
Market Cap:
$2.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Radiopharm Theranostics Ltd
NASDAQ:RADX
|
AU |
|
M
|
Microsoft Corp
F:MSF
|
US |
|
M
|
Morgan Stanley
XMUN:DWD
|
US |
|
Sanofi SA
PAR:SAN
|
FR |
|
L
|
LSI Industries Inc
F:LS2
|
US |
|
N
|
Nokia Oyj
PSE:NOKIA
|
FI |
|
A
|
Arcosa Inc
F:EOB
|
US |
|
M
|
Minth Group Ltd
OTC:MNTHY
|
TW |
|
F
|
Fresenius SE & Co KGaA
XMUN:FRE
|
DE |
|
Orexo AB
F:C5G
|
SE |
Intrinsic Value
Not Available for RADX
There is not enough data to reliably calculate the intrinsic value for Radiopharm Theranostics Ltd.
Do our valuations actually work? See backtest results .
Alternatives to RADX
Fundamental Analysis
What Radiopharm Theranostics Does
Radiopharm Theranostics is a biopharmaceutical company that develops radiopharmaceutical drugs for cancer. These medicines use a radioactive component to help doctors locate tumors with imaging or deliver radiation directly to cancer cells. The company is building a pipeline of diagnostic and therapeutic products rather than selling a broad commercial drug portfolio today.
- Headquarters
- Australia AU
- Employees
- 14
- IPO date
- Nov 25, 2021
Financials
Efficiency
Earnings Waterfall
Radiopharm Theranostics Ltd
Radiopharm Theranostics Ltd
